Proteome Sciences

Proteome Sciences said this week that its SensiDerm multiplex protein assays for detection of sensitizers and allergens in cosmetics have been prioritized for further development by Cosmetics Europe, the European trade organization for the cosmetics, toiletry, and perfumery indus

Proteome Sciences said this week that it has completed an in vivo study of its CK1D-inhibitor Alzheimer's disease therapy, finding that both of its lead compounds improved cognitive function in animal models.

According to a team led by researchers at Plymouth University, there are significant flaws in the standard cognitive test used to diagnose and evaluate Alzheimer's disease patients, which could be hampering efforts to develop treatments and biomarkers for the disease.

Researchers from the University of Wisconsin-Madison have characterized the mitochondrial acetylome, finding significant changes in protein acetylation in response to calorie restriction and activity of the protein deacetylase SIRT3.

Last month, a research team led by Bruno Domon, head of the Luxembourg Clinical Proteomics Center, published a paper in Molecular & Cellular Proteomics demonstrating

University of Geneva researchers in collaboration with the UK's Proteome Sciences have identified a protein marker that could help doctors better determine the time of stroke onset.

NEW YORK (GenomeWeb News) – Proteome Sciences today said that revenues during the first half of 2012 rose 44 percent year over year.

NEW YORK (GenomeWeb News) – Proteome Sciences said today that it will collaborate with CHDI Foundation on research into protein biomarkers for Huntington's disease.

A consortium of researchers working as part of the Alzheimer's Disease Neuroimaging Initiative has completed an analysis of potential plasma protein biomarkers for Alzheimer's in three separate patient cohorts, identifying four analytes associated with the disease.

Proteome Sciences said this week that is has achieved a milestone in the development of inhibitors to casein kinase 1 delta, the company's primary target in its Alzheimer's disease therapeutic program.

Pages

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.